Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer's Disease

B. Svobodova, L. Pulkrabkova, D. Panek, A. Misiachna, M. Kolcheva, R. Andrys, J. Handl, J. Capek, P. Nyvltova, T. Rousar, L. Prchal, V. Hepnarova, M. Hrabinova, L. Muckova, D. Tosnerova, G. Karabanovich, V. Finger, O. Soukup, M. Horak, J. Korabecny

. 2023 ; 24 (11) : . [pub] 20230523

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23011390

Grant support
22-24384S Czech Science Foundation
LX22NPO510 Next Generation EU
DZRO-FVZ22-ZHN II Long term development plan (Faculty of Military Health Sciences) Medical issues of WMD II

Alzheimer's disease (AD) is a complex disease with an unknown etiology. Available treatments, limited to cholinesterase inhibitors and N-methyl-d-aspartate receptor (NMDAR) antagonists, provide symptomatic relief only. As single-target therapies have not proven effective, rational specific-targeted combination into a single molecule represents a more promising approach for treating AD, and is expected to yield greater benefits in alleviating symptoms and slowing disease progression. In the present study, we designed, synthesized, and biologically evaluated 24 novel N-methylpropargylamino-quinazoline derivatives. Initially, compounds were thoroughly inspected by in silico techniques determining their oral and CNS availabilities. We tested, in vitro, the compounds' effects on cholinesterases and monoamine oxidase A/B (MAO-A/B), as well as their impacts on NMDAR antagonism, dehydrogenase activity, and glutathione levels. In addition, we inspected selected compounds for their cytotoxicity on undifferentiated and differentiated neuroblastoma SH-SY5Y cells. We collectively highlighted II-6h as the best candidate endowed with a selective MAO-B inhibition profile, NMDAR antagonism, an acceptable cytotoxicity profile, and the potential to permeate through BBB. The structure-guided drug design strategy applied in this study imposed a novel concept for rational drug discovery and enhances our understanding on the development of novel therapeutic agents for treating AD.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011390
003      
CZ-PrNML
005      
20230801133021.0
007      
ta
008      
230718s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms24119124 $2 doi
035    __
$a (PubMed)37298087
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Svobodova, Barbora $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
245    10
$a Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer's Disease / $c B. Svobodova, L. Pulkrabkova, D. Panek, A. Misiachna, M. Kolcheva, R. Andrys, J. Handl, J. Capek, P. Nyvltova, T. Rousar, L. Prchal, V. Hepnarova, M. Hrabinova, L. Muckova, D. Tosnerova, G. Karabanovich, V. Finger, O. Soukup, M. Horak, J. Korabecny
520    9_
$a Alzheimer's disease (AD) is a complex disease with an unknown etiology. Available treatments, limited to cholinesterase inhibitors and N-methyl-d-aspartate receptor (NMDAR) antagonists, provide symptomatic relief only. As single-target therapies have not proven effective, rational specific-targeted combination into a single molecule represents a more promising approach for treating AD, and is expected to yield greater benefits in alleviating symptoms and slowing disease progression. In the present study, we designed, synthesized, and biologically evaluated 24 novel N-methylpropargylamino-quinazoline derivatives. Initially, compounds were thoroughly inspected by in silico techniques determining their oral and CNS availabilities. We tested, in vitro, the compounds' effects on cholinesterases and monoamine oxidase A/B (MAO-A/B), as well as their impacts on NMDAR antagonism, dehydrogenase activity, and glutathione levels. In addition, we inspected selected compounds for their cytotoxicity on undifferentiated and differentiated neuroblastoma SH-SY5Y cells. We collectively highlighted II-6h as the best candidate endowed with a selective MAO-B inhibition profile, NMDAR antagonism, an acceptable cytotoxicity profile, and the potential to permeate through BBB. The structure-guided drug design strategy applied in this study imposed a novel concept for rational drug discovery and enhances our understanding on the development of novel therapeutic agents for treating AD.
650    _2
$a lidé $7 D006801
650    12
$a Alzheimerova nemoc $x farmakoterapie $7 D000544
650    _2
$a inhibitory MAO $x terapeutické užití $7 D008996
650    12
$a neuroblastom $x farmakoterapie $7 D009447
650    _2
$a cholinesterasové inhibitory $x terapeutické užití $7 D002800
650    _2
$a monoaminoxidasa $x metabolismus $7 D008995
650    _2
$a racionální návrh léčiv $7 D015195
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pulkrabkova, Lenka $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
700    1_
$a Panek, Dawid $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic $u Department of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
700    1_
$a Misiachna, Anna $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic $u Department of Physiology, Faculty of Science, Charles University in Prague, Albertov 6, 128 43 Prague, Czech Republic
700    1_
$a Kolcheva, Marharyta $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic
700    1_
$a Andrys, Rudolf $u Department of Chemistry, Faculty of Science, University Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Handl, Jiri $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic
700    1_
$a Capek, Jan $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic $1 https://orcid.org/0000000237132467
700    1_
$a Nyvltova, Pavlina $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic
700    1_
$a Rousar, Tomas $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic
700    1_
$a Prchal, Lukas $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Hepnarova, Vendula $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
700    1_
$a Hrabinova, Martina $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
700    1_
$a Muckova, Lubica $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000166936061
700    1_
$a Tosnerova, Daniela $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Karabanovich, Galina $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Finger, Vladimir $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000251466850
700    1_
$a Soukup, Ondrej $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
700    1_
$a Horak, Martin $u Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic
700    1_
$a Korabecny, Jan $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000169777596 $7 xx0119837
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 24, č. 11 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37298087 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133018 $b ABA008
999    __
$a ok $b bmc $g 1963671 $s 1197655
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 24 $c 11 $e 20230523 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 22-24384S $p Czech Science Foundation
GRA    __
$a LX22NPO510 $p Next Generation EU
GRA    __
$a DZRO-FVZ22-ZHN II $p Long term development plan (Faculty of Military Health Sciences) Medical issues of WMD II
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options